 | • レポートコード：MRC2303I0193 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の潰瘍性大腸炎市場規模が、予測期間中（2022年-2027年）に年平均5.5%で成長すると予測しています。本書では、潰瘍性大腸炎の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、医薬品別（抗炎症薬、アミノサリチル酸塩、コルチコステロイド、抗TNF生物製剤、免疫抑制剤）分析、疾患別（潰瘍性直腸炎、直腸S状結腸炎、左側大腸炎、汎大腸炎/全大腸炎、劇症大腸炎）分析、地域別（北米、ヨーロッパ、アジア太平洋、南米、中東・アフリカ、アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、その他）分析、競争状況、市場機会・将来の動向など、以下の構成でまとめております。また、AbbVie Inc.（Allergan, Inc.）、Bausch Health Companies Inc.、Johnson and Johnson、Merck & Co., Inc.,、Takeda Pharmaceutical Company Limited、Teva Pharmaceutical Industries Ltd、Pfizer Inc.、Eli Lilly and Company、Novartis AG、Bristol Myers Squibbなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の潰瘍性大腸炎市場規模：医薬品別 - 抗炎症薬の市場規模 - アミノサリチル酸塩の市場規模 - コルチコステロイドの市場規模 - 抗TNF生物製剤の市場規模 - 免疫抑制剤の市場規模 ・世界の潰瘍性大腸炎市場規模：疾患別 - 潰瘍性直腸炎の市場規模 - 直腸S状結腸炎の市場規模 - 左側大腸炎の市場規模 - 汎大腸炎/全大腸炎の市場規模 - 劇症大腸炎の市場規模 ・世界の潰瘍性大腸炎市場規模：地域別 - 北米の潰瘍性大腸炎市場規模 アメリカの潰瘍性大腸炎市場規模 カナダの潰瘍性大腸炎市場規模 メキシコの潰瘍性大腸炎市場規模 … - ヨーロッパの潰瘍性大腸炎市場規模 ドイツの潰瘍性大腸炎市場規模 イギリスの潰瘍性大腸炎市場規模 フランスの潰瘍性大腸炎市場規模 … - アジア太平洋の潰瘍性大腸炎市場規模 中国の潰瘍性大腸炎市場規模 インドの潰瘍性大腸炎市場規模 日本の潰瘍性大腸炎市場規模 … - 中東・アフリカの潰瘍性大腸炎市場規模 GCC諸国の潰瘍性大腸炎市場規模 南アフリカの潰瘍性大腸炎市場規模 … - 南米の潰瘍性大腸炎市場規模 ブラジルの潰瘍性大腸炎市場規模 アルゼンチンの潰瘍性大腸炎市場規模 … - その他地域の潰瘍性大腸炎市場規模 ・競争状況 ・市場機会・将来の動向 |
The ulcerative colitis market is expected to register a CAGR of 5.5% during the forecast period (2022-2027).
The medical and psycho-socioeconomic effects of the COVID-19 pandemic and pre-existing medical conditions such as acute severe ulcerative colitis were multidirectional and influenced the welfare of patients. According to a research study titled “Acute severe ulcerative colitis: confronting an intensified stressor during the COVID-19 pandemic” published in February 2021, the risk of adverse outcomes of COVID-19 has been reported to be higher in patients with ulcerative colitis. It continues to be a threat to patients with acute severe ulcerative colitis, posing an ever-growing risk to the global healthcare system. Thus, COVID-19 has had a significant impact on the growth of the market over the forecast period.
Factors such as the growing burden of ulcerative colitis, increasing patient assistance programs, and technological advancements coupled with increasing research are driving the growth of the market.
Ulcerative colitis (UC) is the most common form of inflammatory bowel disease and affects several people. According to a research article by Whitney D. Lynch et al., updated in June 2022, globally, ulcerative colitis has an incidence of 9 to 20 cases per 100,000 people per year. Its prevalence is 156 to 291 cases per 100,000 people per year. Ulcerative colitis has a higher prevalence in adults. Such a high burden of disease is expected to drive the growth of the market.
The increasing involvement of key players in product development related to the field is anticipated to drive the market’s growth. For instance, in June 2021, in Japan, Takeda Pharmaceutical Company Limited started a phase III clinical trial to assess the efficacy and safety of intravenous (IV) Vedolizumab in Japanese patients with moderate to severe ulcerative colitis. The trial is expected to be completed in September 2024. This increasing focus of market players on the development of drugs for treatment is expected to boost the growth of the market in the future.
Additionally, the approval of the drugs is also propelling the growth of the market. For instance, in November 2021, Bristol Myers Squibb received marketing authorization from the European Commission for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or are intolerant to either conventional therapy or a biologic agent.
Thus, the aforesaid factors are expected to boost the market’s growth over the forecast period. However, factors such as high levels of unmet clinical need in ulcerative colitis (UC) and the side effects of medications are expected to impede market growth over the forecast period.
Ulcerative Colitis Market Trends
Ulcerative Proctitis Segment is Expected to Experience the Fastest Growth Over the Forecast Period
Ulcerative proctitis is one of the types of ulcerative colitis. It is considered the initial manifestation of ulcerative colitis, in which fine ulcerations in the inner linings of the mucosa of the large intestine are observed.
According to a research study by Anupam Kumar Singh et al., published in the United European Gastroenterology Journal in March 2021, the incidence rate of COVID-19 per 1,000 patients with inflammatory bowel disease (ulcerative colitis) and the general population was 4.02 and 6.59, respectively. The proportion of COVID-19-positive inflammatory bowel disease patients requiring hospitalization and intensive care unit care was 27.29% and 5.33%. The relative risks of hospitalization, intensive care unit admission, and mortality were lower for patients on biological agents but higher for patients on steroids or 5-aminosalicylate use. Thus, the SARS-CoV-2 infection risk in patients with inflammatory bowel disease was considerable in the general population. The outcomes of COVID-19-positive inflammatory bowel disease patients were worse in ulcerative colitis than those on steroids or 5-aminosalicylates.
Additionally, the launch of drugs by different market players is also propelling the growth of the market segment. For instance, in April 2021, Teva Pharmaceuticals USA, Inc., launched its 1000 mg generic version of Casana (mesalamine) suppository medicine used to treat adults with active ulcerative proctitis (ulcerative rectal colitis) in the United States.
Furthermore, the increasing number of research studies on drugs for the treatment of ulcerative proctitis is also contributing to the growth of the market. For instance, in October 2021, First Wave Biopharma Inc. dosed the first patient in a Phase 2b clinical trial investigating a topical formulation of niclosamide (FW-UP) as a potential treatment for patients with ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS). Such increasing research activities are also boosting the growth of the market segment.
Thus, owing to the abovementioned factors, the market segment is expected to show significant growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market Over the Forecasted Period
North America is expected to lead the ulcerative colitis market, owing to the presence of key players and the increasing prevalence of ulcerative colitis in the region, along with the continuing funding for the development of new therapeutics for the treatment of the condition.
The increasing research activities by the market players are also contributing to the growth of the market. For instance, in March 2021, in Canada, Eli Lilly and Company initiated a phase II clinical trial to assess the efficacy and safety of LY3471851 in adult patients with active ulcerative colitis (UC). The study is expected to be completed in October 2024. Thus, the above factors are expected to drive market growth over the forecast period in the region.
Additionally, the approvals from regulatory authorities such as the United States Food and Drug Administration, Health Canada, and others are also propelling the growth of the market. For instance, in May 2021, Bristol Myers Squibb received approval from the United States Food and Drug Administration (FDA) for Zeposia (ozanimod) in the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).
Thus, owing to the abovementioned factors, the studied market in the North American region is expected to project growth over the forecast period.
Ulcerative Colitis Market Competitor Analysis
The ulcerative colitis market is moderately competitive. The companies implement certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships, that help them strengthen their market position. Some of the market players include Bausch Health Companies Inc., Johnson & Johnson, Merck & Co., Inc., AbbVie Inc. (Allergan, Inc.), and Novartis AG, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Global Incidence and Prevalence of Ulcerative Colitis
4.2.2 Technological Advancements
4.2.3 Increase in Patient Assistance Programs
4.3 Market Restraints
4.3.1 High Levels of Unmet Clinical Need in Ulcerative Colitis (UC)
4.3.2 Side-effects of Medications
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Drug Type
5.1.1 Anti-Inflammatory Drugs
5.1.1.1 Aminosalicylates
5.1.1.2 Corticosteroids
5.1.2 Anti-TNF biologics
5.1.3 Immunosuppressant
5.1.4 Calcineurin Inhibitors
5.1.5 Other Drug Types
5.2 By Disease Type
5.2.1 Ulcerative Proctitis
5.2.2 Proctosigmoiditis
5.2.3 Left-sided Colitis
5.2.4 Pancolitis or Universal Colitis
5.2.5 Fulminant Colitis
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc. (Allergan, Inc.)
6.1.2 Bausch Health Companies Inc.
6.1.3 Johnson and Johnson
6.1.4 Merck & Co., Inc.,
6.1.5 Takeda Pharmaceutical Company Limited
6.1.6 Teva Pharmaceutical Industries Ltd
6.1.7 Pfizer Inc.
6.1.8 Eli Lilly and Company
6.1.9 Novartis AG
6.1.10 Bristol Myers Squibb
6.1.11 Mitsubishi Tanabe Pharma Corporation
6.1.12 Sun Pharmaceutical Industries Ltd.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS